Schistosoma - Revision history

Aidan at 13:50, 18 November 2025

2025-11-18T13:50:01Z

← Older revision		Revision as of 13:50, 18 November 2025
Line 70:		Line 70:
	*Chronic granulomatous inflammation causes weight loss, anemia, stunted growth		*Chronic granulomatous inflammation causes weight loss, anemia, stunted growth
	*[[Eosinophilia]] is common		*[[Eosinophilia]] is common

			=== Pulmonary Hypertension ===

			* Primarily [[Schistosoma mansoni]][[CiteRef::knafl2020sc]]

	==Investigations==		==Investigations==

2025-04-24T15:08:51Z

Background

← Older revision		Revision as of 15:08, 24 April 2025
Line 1:		Line 1:
	==Background==		==Background==

			*Trematode (blood fluke)
	*Infection with a species of the genus ''Schistosoma''

	===Microbiology===		===Microbiology===

			*Three main species affecting humans:
	*[[Schistosoma mansoni]]: liver and gut
	*[[Schistosoma ~~haematobium~~]]: ~~GU/pelvis~~		**[[Schistosoma mansoni]]: liver and gut
	*[[Schistosoma ~~japonicum~~]]: ~~liver and gut~~		**[[Schistosoma haematobium]]: GU/pelvis
	*[[Schistosoma ~~mekongi~~]]: ~~Mekong~~ ~~basin~~		**[[Schistosoma japonicum]]: liver and gut
			*Also: [[Schistosoma mekongi]], [[Schistosoma intercalatum]], [[Schistosoma guineensis]], and case reports of hybrid schistosomes of cattle origin that can infect humans
			*Non-human-host schistosomes (of birds and mammals) can cause [[cercarial dermatitis]]

	===Risk Factors===		===Risk Factors===

2025-04-24T15:06:11Z

← Older revision		Revision as of 15:06, 24 April 2025
Line 25:		Line 25:
	\|-		\|-
	\|Middle East and northern Africa		\|Middle East and northern Africa
	\|[[Schistosoma haematobium]][[Schistosoma mansoni]] (sporadic reports in Arabian Peninsula)		\|[[Schistosoma haematobium]], [[Schistosoma mansoni]] (sporadic reports in Arabian Peninsula)
	\|6%		\|6%
	\|-		\|-
	\|Sub-Saharan Africa		\|Sub-Saharan Africa
	\|[[Schistosoma mansoni]][[Schistosoma haematobium]][[Schistosoma intercalatum]] (DRC)		\|[[Schistosoma mansoni]], [[Schistosoma haematobium]], [[Schistosoma intercalatum]] (DRC), [[Schistosoma guineensis]] (West Africa)
	[[Schistosoma guineensis]] (West Africa)
	\|24%		\|24%
	\|-		\|-
Line 38:		Line 37:
	\|-		\|-
	\|East Asia and the Pacific		\|East Asia and the Pacific
	\|[[Schistosoma japonicum]] (China, Philippines, Sulawesi)		\|[[Schistosoma japonicum]] (China, Philippines, Sulawesi), [[Schistosoma mekongi]] (Cambodia, Laos)
	[[Schistosoma mekongi]] (Cambodia, Laos)
	\|5%		\|5%
	\|}		\|}

2025-04-24T15:05:30Z

@@ Line 5: / Line 5: @@
 ===Microbiology===
-*''[[Schistosoma mansoni]]'': liver and gut
+*[[Schistosoma mansoni]]: liver and gut
-*''[[Schistosoma haematobium]]'': GU/pelvis
+*[[Schistosoma haematobium]]: GU/pelvis
-*''[[Schistosoma japonicum]]'': liver and gut
+*[[Schistosoma japonicum]]: liver and gut
-*''[[Schistosoma mekongi]]'': Mekong basin
+*[[Schistosoma mekongi]]: Mekong basin
 ===Risk Factors===
@@ Line 15: / Line 15: @@
 === Epidemiology ===
 ==Clinical Manifestations==

2024-09-23T14:15:37Z

← Older revision		Revision as of 14:15, 23 September 2024
Line 65:		Line 65:
	* Usually based on serology		* Usually based on serology
	** Can cross-react with other helminth co-infections, including [[trichinosis]] and [[filariasis]]		** Can cross-react with other helminth co-infections, including [[trichinosis]] and [[filariasis]]
			** Can remain positive and even fluctuate for years after cure[[CiteRef::yong2010lo]]
	** Can remain positive and even fluctuate for years after cure<ref>Michelle K. Yong, FRACP and others, Long‐Term Follow‐Up of ''Schistosomiasis'' Serology Post‐Treatment in Australian Travelers and Immigrants, ''Journal of Travel Medicine'', Volume 17, Issue 2, 1 March 2010, Pages 89–93, https://doi.org/10.1111/j.1708-8305.2009.00379.x</ref>

	==Management==		==Management==

2023-07-11T14:33:40Z

Management

← Older revision		Revision as of 14:33, 11 July 2023
Line 73:		Line 73:
	*Chronic		*Chronic
	**[[Is treated by::Praziquantel]] 20-40 mg/kg or 40-60 mg/kg (if at risk for ''S. japonica'')		**[[Is treated by::Praziquantel]] 20-40 mg/kg or 40-60 mg/kg (if at risk for ''S. japonica'')
	**Given over one day split into 3 doses~~, then repeated 6 weeks later~~		**Given over one day split into 3 doses
			**May be repeated 6 weeks later, though this practice is not universal
	**No role for test-of-cure serology		**No role for test-of-cure serology

2023-06-12T16:03:57Z

Diagnosis

← Older revision		Revision as of 16:03, 12 June 2023
Line 55:		Line 55:
	*Labs		*Labs
	**CBC, showing eosinophilia		**CBC, showing eosinophilia
	**~~Schisto~~ serology (only positive 6 weeks after infection)		**Schistosoma serology (only positive 6 weeks after infection)
	**Egg detection in stool, urine, semen, or tissue biopsy		**Egg detection in stool, urine, semen, or tissue biopsy
	*Imaging		*Imaging
Line 65:		Line 65:
	* Usually based on serology		* Usually based on serology
	** Can cross-react with other helminth co-infections, including [[trichinosis]] and [[filariasis]]		** Can cross-react with other helminth co-infections, including [[trichinosis]] and [[filariasis]]
			** Can remain positive and even fluctuate for years after cure<ref>Michelle K. Yong, FRACP and others, Long‐Term Follow‐Up of ''Schistosomiasis'' Serology Post‐Treatment in Australian Travelers and Immigrants, ''Journal of Travel Medicine'', Volume 17, Issue 2, 1 March 2010, Pages 89–93, https://doi.org/10.1111/j.1708-8305.2009.00379.x</ref>

	==Management==		==Management==
Line 73:		Line 74:
	**[[Is treated by::Praziquantel]] 20-40 mg/kg or 40-60 mg/kg (if at risk for ''S. japonica'')		**[[Is treated by::Praziquantel]] 20-40 mg/kg or 40-60 mg/kg (if at risk for ''S. japonica'')
	**Given over one day split into 3 doses, then repeated 6 weeks later		**Given over one day split into 3 doses, then repeated 6 weeks later
			**No role for test-of-cure serology

	==Prognosis==		==Prognosis==

2022-01-25T16:44:20Z

← Older revision		Revision as of 16:44, 25 January 2022
Line 78:		Line 78:
	*Increased risk of squamous cell carcinoma, which increase with young age at infection, duration of infection, high burden of infection, and bladder wall fibrosis		*Increased risk of squamous cell carcinoma, which increase with young age at infection, duration of infection, high burden of infection, and bladder wall fibrosis

	{{DISPLAYTITLE:''Schistosoma'' ~~species~~}}		{{DISPLAYTITLE:''Schistosoma''}}
	[[Category:Protozoa]]		[[Category:Protozoa]]

2022-01-25T16:44:12Z

Aidan moved page Schistosoma species to Schistosoma without leaving a redirect

← Older revision	Revision as of 16:44, 25 January 2022
(No difference)

2021-09-02T13:39:27Z

Background

← Older revision		Revision as of 13:39, 2 September 2021
Line 13:		Line 13:

	*Fresh water exposure in endemic countries		*Fresh water exposure in endemic countries

			=== Epidemiology ===

			* Seroprevalence in migrants by region of origin[[CiteRef::asundi2019pr]]
			** Latin America and the Caribbean (20%; 9-34)
			** Middle East and north Africa (6.4%; 0.3-19.5)
			** Sub-Saharan Africa (24.1%; 16-33)
			** South Asia (0%; 0-69)
			** East Asia and the Pacific (5.4%; 2-10)

	==Clinical Manifestations==		==Clinical Manifestations==